177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs

ESMO shared on LinkedIn:

“ESMOGI24: Promising data from the phase III NETTER-2 study show that peptide receptor radionuclide therapy significantly improves outcomes for patients with grade 2 high-grade 3 low gastroenteropancreatic neuroendocrine tumours (GEP-NETs), regardless of tumour grade or primary origin.

According to Rocio Garcia-Carbonero, commenting on these results for the ESMO Daily Reporter, this study supports the use of 177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs, and possibly selected patients with grade 2 high GEP-NETs.”

Source: ESMO/LinkedIn